<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03370536</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 40-5004</org_study_id>
    <nct_id>NCT03370536</nct_id>
  </id_info>
  <brief_title>ECGi Ibutilide: Effect of Ibutilide on AF Source Location and Organization</brief_title>
  <official_title>Panoramic ECGi to Guide Ablation of Non-Paroxysmal AF: Effect of Ibutilide on AF Source Location and Organization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vivek Reddy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, non-randomized, un-blinded, observational trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, multicenter observational study will examine the ability of ECGi mapping to

        1. Effect of Ibutilide on the number and size of the driver domains

        2. Effect of ablation of Ibutilide-organized driver domains

        3. Effect of PV isolation on driver domains

      The researchers hypothesize that this approach will lead to successful arrhythmia control .
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    1 patient enrolled (consented) but screen failed. Study stopped as unable to enroll.
  </why_stopped>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Actual">July 18, 2018</completion_date>
  <primary_completion_date type="Actual">July 18, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who no Longer Has Recurrent At/AF</measure>
    <time_frame>at 12 months</time_frame>
    <description>Freedom from recurrent At/AF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Drivers</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of drivers identified</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of Drivers</measure>
    <time_frame>Baseline</time_frame>
    <description>Size of drivers ablated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change of Driver Regions</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>Percent change of driver regions after ibutilide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF Termination Rate</measure>
    <time_frame>post ablation inducibility of AF after 5 minutes of burst pacing</time_frame>
    <description>AF termination rate is defined as AF termination to AT/SR (Atrial Tachycardia/Sinus Rhythm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Procedure Time</measure>
    <time_frame>within 24 hours after the procedure is completed the time is calculated</time_frame>
    <description>Total duration of RF ablation/fluoroscopy time/exposure procedure time</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Patients with AF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with AF and planned to undergo first catheter procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CardioInsight ECGI Mapping System</intervention_name>
    <description>The CardioInsight mapping system is a noninvasive, single beat cardiac arrhythmia mapping system that provides 3D electroanatomic maps of the heart.</description>
    <arm_group_label>Patients with AF</arm_group_label>
    <other_name>ECGi mapping</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AF ablation</intervention_name>
    <description>Empiric ablation (CFAE or linear ablation) is not permitted</description>
    <arm_group_label>Patients with AF</arm_group_label>
    <other_name>Biosense Thermocool SF</other_name>
    <other_name>Biosense Smart Touch SF (STSF)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibutilide</intervention_name>
    <description>Progressive doses of Ibutilide administered (0.25mg, then 0.25mg, then 0.5mg)</description>
    <arm_group_label>Patients with AF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years of age.

          -  ° Symptomatic persistent AF refractory or intolerant to at least 1 class I or III
             antiarrhythmic medication Persistent AF - defined as Persistent: AF that is sustained
             &gt; 7 days. Episodes of AF which are terminated by electrical or pharmacologic
             cardioversion after ≥ 48 hours of AF, but prior to 7 days, should also be classified
             as persistent AF episodes.

               -  Planned to undergo first catheter ablation procedure ( prior atrial flutter
                  typical is allowed)

          -  Ability to understand the requirements of the study and sign the informed consent
             form.

          -  Willingness to adhere to study restrictions and comply with all post-procedural
             follow-up requirements

          -  Projected lifespan greater than 1 year

        Exclusion Criteria:

          -  They have baseline prolonged QT or renal failure precluding safe used of ibutilide

          -  Rheumatic heart disease,

          -  Current intra-cardiac thrombus,

          -  History of MI or CABG within 6 weeks;

          -  Class IV HF,

          -  Unable to sign consent

          -  Projected lifespan of &lt; 1 year

          -  Women known to be pregnant or to have positive beta-HCG.

          -  Participation in another study that would interfere with this study.

          -  Unstable Angina

          -  Recent cerebral ischemic events

          -  Contraindication to anticoagulation

          -  Prior history of polymorphic ventricular tachycardia or torsades de pointes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Koruth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vivek Reddy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 4, 2017</study_first_submitted>
  <study_first_submitted_qc>December 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2017</study_first_posted>
  <results_first_submitted>January 28, 2020</results_first_submitted>
  <results_first_submitted_qc>January 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2020</results_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Vivek Reddy</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Persistent Atrial Fibrillation</keyword>
  <keyword>AFIB</keyword>
  <keyword>Arrhythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibutilide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT03370536/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients With AF</title>
          <description>Patients with AF and planned to undergo first catheter procedure
CardioInsight ECGI Mapping System: The CardioInsight mapping system is a noninvasive, single beat cardiac arrhythmia mapping system that provides 3D electroanatomic maps of the heart.
AF ablation: Empiric ablation (CFAE or linear ablation) is not permitted
Ibutilide: Progressive doses of Ibutilide administered (0.25mg, then 0.25mg, then 0.5mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients With Atrial Fibrillation (AF)</title>
          <description>Patients with AF and planned to undergo first catheter procedure</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who no Longer Has Recurrent At/AF</title>
        <description>Freedom from recurrent At/AF</description>
        <time_frame>at 12 months</time_frame>
        <population>Participant screen failed</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With Atrial Fibrillation (AF)</title>
            <description>Patients with AF and planned to undergo first catheter procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who no Longer Has Recurrent At/AF</title>
          <description>Freedom from recurrent At/AF</description>
          <population>Participant screen failed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Drivers</title>
        <description>Number of drivers identified</description>
        <time_frame>Baseline</time_frame>
        <population>Participant screen failed</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With Atrial Fibrillation (AF)</title>
            <description>Patients with AF and planned to undergo first catheter procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Drivers</title>
          <description>Number of drivers identified</description>
          <population>Participant screen failed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Size of Drivers</title>
        <description>Size of drivers ablated</description>
        <time_frame>Baseline</time_frame>
        <population>Participant screen failed</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With Atrial Fibrillation (AF)</title>
            <description>Patients with AF and planned to undergo first catheter procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Size of Drivers</title>
          <description>Size of drivers ablated</description>
          <population>Participant screen failed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of Driver Regions</title>
        <description>Percent change of driver regions after ibutilide</description>
        <time_frame>Baseline and 1 year</time_frame>
        <population>Participant screen failed</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With Atrial Fibrillation (AF)</title>
            <description>Patients with AF and planned to undergo first catheter procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Driver Regions</title>
          <description>Percent change of driver regions after ibutilide</description>
          <population>Participant screen failed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AF Termination Rate</title>
        <description>AF termination rate is defined as AF termination to AT/SR (Atrial Tachycardia/Sinus Rhythm)</description>
        <time_frame>post ablation inducibility of AF after 5 minutes of burst pacing</time_frame>
        <population>Participant screen failed</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With Atrial Fibrillation (AF)</title>
            <description>Patients with AF and planned to undergo first catheter procedure</description>
          </group>
        </group_list>
        <measure>
          <title>AF Termination Rate</title>
          <description>AF termination rate is defined as AF termination to AT/SR (Atrial Tachycardia/Sinus Rhythm)</description>
          <population>Participant screen failed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Procedure Time</title>
        <description>Total duration of RF ablation/fluoroscopy time/exposure procedure time</description>
        <time_frame>within 24 hours after the procedure is completed the time is calculated</time_frame>
        <population>Participant screen failed</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With Atrial Fibrillation (AF)</title>
            <description>Patients with AF and planned to undergo first catheter procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Total Procedure Time</title>
          <description>Total duration of RF ablation/fluoroscopy time/exposure procedure time</description>
          <population>Participant screen failed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Participant screen failed</desc>
      <group_list>
        <group group_id="E1">
          <title>Patients With Atrial Fibrillation (AF)</title>
          <description>Patients with AF and planned to undergo first catheter procedure</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Vivek Reddy</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>(212) 241-7114</phone>
      <email>vivek.reddy@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

